Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL5982581 | 0.87 | TSHR (0.46) | GPR35ALDH1A1TSHRTDP1HPGD | |
| SCHEMBL14845129 | 0.87 | GPR35 (0.49) | GPR35ALDH1A1TSHRTDP1HPGD | |
| SCHEMBL3933610 | 0.85 | GPR35 (0.58) | GPR35ALDH1A1TSHRTDP1HPGD | |
| SCHEMBL249846 | 0.85 | ALDH1A1 (0.68) | GPR35ALDH1A1TSHRTDP1HPGD | |
| SCHEMBL94768 | 0.84 | TSHR (0.52) | GPR35ALDH1A1TSHRTDP1HPGD | |
| SCHEMBL9641198 | 0.82 | TSHR (0.55) | GPR35ALDH1A1TSHRTDP1HPGD | |
| Nitric Acid SCHEMBL9873962 | 0.81 | ALDH1A1 (0.63) | GPR35ALDH1A1TSHRTDP1HPGD | |
| SCHEMBL1436652 | 0.81 | TSHR (0.41) | GPR35ALDH1A1TSHRTDP1SMN1; SMN2 | |
| SCHEMBL6108468 | 0.81 | ALDH1A1 (0.60) | ALDH1A1TSHRTDP1HPGDSMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL8413128 | 0.81 | ALDH1A1 (0.49) | GPR35ALDH1A1TSHRTDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
| EP-1325016-A2 | NUCLEOSIDE DERIVATIVES AND A METHOD FOR PRODUCING THE SAME | Epigenomics AG (DE) | 2003-07-09 | — | — | EP | disclosed |
| WO-2001012642-A2 | NUCLEOSIDE DERIVATIVES AND A METHOD FOR PRODUCING SAME | EPIGENOMICS AG (DE) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | GPR35 4113/4885ALDH1A1 2948/4885TSHR 3439/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | GPR35 522/4885ALDH1A1 2458/4885TSHR 110/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | GPR35 522/4885ALDH1A1 2458/4885TSHR 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.